MARKET

HGEN

HGEN

Humanigen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.86
-0.25
-4.09%
After Hours: 5.87 +0.01 +0.17% 18:47 11/29 EST
OPEN
6.20
PREV CLOSE
6.11
HIGH
6.32
LOW
5.83
VOLUME
1.54M
TURNOVER
--
52 WEEK HIGH
29.20
52 WEEK LOW
5.59
MARKET CAP
373.97M
P/E (TTM)
-1.3970
1D
5D
1M
3M
1Y
5Y
20 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results were down year over year.
Benzinga · 14h ago
Humanigen Announces Abstracts Accepted For The British Thoracic Society Winter Meeting 2021
Abstract #S48 describes top-line results from the Humanigen Phase 3 LIVE-AIR study in hospitalized COVID-19 patients, which reveal a 54% relative improvement in the likelihood of survival without invasive
Benzinga · 11/22 11:33
Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
BURLINGAME, Calif., November 16, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that its presentation time at the...
Business Wire · 11/16 12:47
University Of Notre Dame Du Lac Buys Bath & Body Works Inc, Pegasystems Inc, Intuit Inc, ...
GuruFocus News · 11/15 14:39
Humanigen EPS misses by $0.14, beats on revenue
Humanigen (NASDAQ:HGEN): Q3 GAAP EPS of -$1.12 misses by $0.14. Revenue of $1.04M beats by $0.97M. Press Release As of September 30, 2021, the company had cash and cash equivalents
Seekingalpha · 11/12 21:06
Humanigen Q3 Sales $1.04M
Humanigen (NASDAQ:HGEN) reported $1.04 million in sales this quarter.
Benzinga · 11/12 21:01
Humanigen Q3 Net Loss Widens Compared With Year-Ago Quarter
MT Newswires · 11/12 16:19
Humanigen Announces Clinical Trial Collaboration To Evaluate Lenzilumab In Acute Graft Versus Host Disease
Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom The "Risk Adapted Therapy
Benzinga · 11/11 11:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HGEN. Analyze the recent business situations of Humanigen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

22.22%Strong Buy
33.33%Buy
33.33%Hold
11.11%Under-perform
0.00%Sell
Analyst Price Target
The average HGEN stock price target is 21.13 with a high estimate of 43.00 and a low estimate of 6.00.
High43.00
Average21.13
Low6.00
Current 5.86
EPS
Actual
Estimate
-1.00-0.75-0.50-0.25
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 88
Institutional Holdings: 30.08M
% Owned: 47.13%
Shares Outstanding: 63.82M
TypeInstitutionsShares
Increased
36
8.22M
New
13
817.24K
Decreased
20
2.16M
Sold Out
20
3.53M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.08%
Pharmaceuticals & Medical Research
-0.15%
Key Executives
Chairman/Chief Executive Officer/Director
Cameron Durrant
Chief Financial Officer/Chief Operating Officer/Chief Accounting Officer/Chief Administrative Officer
Timothy Morris
Senior Vice President/Director of Investor Relations
Ken Trbovich
Chief Scientific Officer/Director
Dale Chappell
Other
Edward Jordan
Independent Director
Ronald Barliant
Independent Director
Rainer Boehm
Independent Director
Cheryl Buxton
Independent Director
John Hohneker
Independent Director
Y. Kevin Xie
No Data
About HGEN
Humanigen, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing immuno-oncology and immunology monoclonal antibodies. The Company’s Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily for chronic conditions. It is focused on development of lead product candidate lenzilumab, a Humaneered anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody. Lenzilumab is a monoclonal antibody designed to target and neutralize human GM-CSF and prevents outcomes related to COVID-19. It is also developing lenzilumab as a treatment for autoimmune and other inflammatory conditions, including eosinophilic asthma, rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), atopic dermatitis (AD) and systemic lupus erythematosus (SLE).

Webull offers kinds of Humanigen Inc stock information, including NASDAQ:HGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HGEN stock methods without spending real money on the virtual paper trading platform.